|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,145.00 JPY | -0.09% |
|
-0.02% | +2.48% |
| 12:20pm | Lupin Receives U.S. FDA Tentative Approval for Enzalutamide Tablets | MT |
| 06-24 | Merck Wins European Commission Approval for KEYTRUDA Plus Padcev in Bladder Cancer | MT |
| Market Cap | 3,846B 23.79B 20.9B 19.26B 18.01B 33.77B 2,245B 34.39B 231B 89.49B 1,107B 89.36B 87.4B | P/E 2027 * |
11x | P/E 2028 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3,744B 23.16B 20.34B 18.74B 17.52B 32.87B 2,185B 33.47B 225B 87.1B 1,077B 86.97B 85.06B | EV / Sales 2027 * |
1.67x | EV / Sales 2028 * | 1.68x |
| Free-Float |
98.88% | Yield 2027 * |
3.75% | Yield 2028 * | 3.87% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -0.09% | ||
| 1 week | -0.02% | ||
| Current month | -6.04% | ||
| 1 month | -3.96% | ||
| 3 months | -15.38% | ||
| 6 months | +2.19% | ||
| Current year | +2.48% |
| 1 week | 2,122 |  | 2,181 |
| 1 month | 2,041 | | 2,283 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,365 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 10/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 01/11/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 01/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 10/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 01/06/2019 |
| Director/Board Member | 58 | 01/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | -0.02% | +54.87% | -2.01% | 23.79B | |
| +0.93% | +2.65% | +42.33% | +145.77% | 1,006B | |
| +1.61% | +7.22% | +60.81% | +47.98% | 589B | |
| +3.51% | +12.31% | +31.15% | +78.88% | 430B | |
| -0.78% | +5.11% | +29.26% | +21.27% | 331B | |
| -0.34% | +5.95% | +38.23% | +24.18% | 288B | |
| -1.24% | +5.27% | +29.70% | +40.06% | 285B | |
| -2.00% | +5.67% | -28.17% | -42.41% | 213B | |
| +0.40% | +4.51% | +25.85% | +55.35% | 190B | |
| -1.05% | +0.06% | +16.91% | +59.86% | 154B | |
| Average | +0.10% | +5.23% | +30.09% | +42.89% | 350.96B | |
| Weighted average by Cap. | +0.63% | +5.33% | +35.27% | +69.76% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,244B 13.88B 12.19B 11.23B 10.5B 19.7B 1,310B 20.06B 135B 52.21B 646B 52.13B 50.99B | 2,069B 12.8B 11.24B 10.36B 9.68B 18.16B 1,208B 18.5B 124B 48.13B 595B 48.06B 47.01B |
| Net income | 350B 2.16B 1.9B 1.75B 1.64B 3.07B 204B 3.13B 21.02B 8.14B 101B 8.13B 7.95B | 328B 2.03B 1.78B 1.64B 1.53B 2.88B 191B 2.93B 19.69B 7.63B 94.33B 7.62B 7.45B |
| Net Debt | -103B -636M -558M -514M -481M -902M -59.99B -919M -6.17B -2.39B -29.57B -2.39B -2.33B | -371B -2.29B -2.01B -1.86B -1.74B -3.25B -216B -3.31B -22.27B -8.62B -107B -8.61B -8.42B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | ¥2,145.00 | -0.09% | 6,216,800 |
| 25/06/26 | ¥2,147.00 | -0.58% | 4,672,000 |
| 24/06/26 | ¥2,159.50 | +1.24% | 5,998,200 |
| 23/06/26 | ¥2,133.00 | -2.02% | 6,256,400 |
| 22/06/26 | ¥2,177.00 | +1.47% | 5,402,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Select your edition
All financial news and data tailored to specific country editions
